HRR and Fanconi Anemia genomic abnormalities have been associated with responses to PARP inhibitors [150,151,423] and CDK12 mutations were associated in preclinical studies with immunotherapy sensitivity [305] and in HRR, affecting DNA damage response genes [712]. The gene discussed is CDK12; the disease is Fanconi anemia.